Merck And J&J Settle Remicade Dispute By Redrawing The Map
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson Inc. and Merck & Co. Inc. settled their two-year dispute over Remicade (infliximab) and its successor Simponi (golimumab) April 15, avoiding an arbitrator's decision by striking a revised agreement under which each will retain some territorial rights to the drugs